DFine Inc., the World’s leading developer of Radio Frequency Kyphoplasty
products, minimally invasive solutions for treating vertebral
compression fractures (VCFs), today announced the appointment of Mr.
Kevin Mosher, as Chief Executive Officer, effective November 16, 2009.
Mr. Mosher comes to DFine from Nobel Biocare, where he served as
President of their North American division. During his tenure at Nobel
Biocare, Mosher helped grow and build an organization known for its
stellar sales execution and consistent profitability. He was a member of
the Executive Committee since joining in 2004, and helped guide the
organization through several acquisitions and a more than doubling of
the company’s organic revenues.
“DFine has a premier Kyphoplasty platform that is poised to become a
leader in the minimally invasive treatment of VCFs,” said Mosher. “I
look forward to building upon this impressive market entry, and driving
this world class organization to the next level.”
Throughout his career, Mosher has distinguished himself as a builder of
businesses that consistently exceed their executional goals. Prior to
his position at Nobel Biocare, Mosher served as President of medical
device manufacturer Masimo Corporation, and spent over 11 years rising
through the sales and marketing ranks at medical device stalwarts such
as Baxter Healthcare and Johnson & Johnson. Mosher holds an Applied
Engineering degree from the U.S. Naval Academy.
“After conducting an extensive nationwide search, DFine’s Board of
Directors believes we have chosen an excellent leader who will guide and
focus our efforts in the coming years. Kevin Mosher brings the perfect
combination of vision and execution to his new role,” said Russell
Hirsch Ph.D. M.D., Managing Director of Prospect Venture Partners. Csaba
Truckai, founder and current CEO of DFine says, “During this natural
evolution of our team, we will benefit tremendously from Kevin’s
leadership, experience and his proven ability to grow businesses. I look
forward to working closely with him in my new role as Chief Technology
Officer of DFine.”
Dr. Rodney Perkins, Chairman of the Board added, “The combination of
Kevin’s strategic sales and marketing experience, Csaba’s innovative
product development and our strong financial support positions us well
to become the leader in the next generation of minimally invasive
vertebral compression fracture treatments.”
ABOUT DFine, Inc.
DFine, Inc. (www.dfineinc.com),
founded in 2004, is a medical device company based in San Jose,
California.
DFine Europe GmbH located in Mannheim, Germany is a subsidiary of DFine,
Inc., and a member of the German Medical Technology Association.
DFine's mission is to develop and market medical devices that treat
vertebral compression fractures and other spinal disorders in a
minimally invasive manner to improve patient quality of life.
DFine’s RF Kyphoplasty procedure with the StabiliT™ Vertebral
Augmentation System is the next generation in kyphoplasty. It combines
the benefits of site-specific cavity creation, controlled cement
delivery, and potential for height restoration with ultra-high viscosity
StabiliT™ ER2 Bone Cement. During the procedure,
radiofrequency energy is applied to specially formulated
energy-responsive bone cement to create ultra-high viscosity cement. The
cement is delivered into a cavity within the vertebra using a hand
switch that allows the physician to remain up to 10 feet from the
fluoroscopic field, potentially reducing the physician’s exposure to
radiation.
The first RF Kyphoplasty cases were conducted in Europe as part of the
SPACE clinical study in December of 2006. US spine specialists began
performing RF Kyphoplasty with the StabiliT™ Vertebral Augmentation
System in April of 2008, while commercialization in Europe began in
February of 2009.
DFine
David Simpson, 408-396-9800
Vice President Sales &
Marketing
daves@dfineinc.com
